Quantitative detection of ANTI-PROTEIN S antibodies of SARS-CoV-2 in vaccinated personnel of Fundación para el Progreso de la Medicina (Foundation for the Progress of Medicine), city of Córdoba, Argentina
Abstract Vaccination against SARS-CoV-2 began in Argentina in December 2020. We measured the concentration of antibodies generated by the different vaccines and doses with the aim of evaluating the humoral immune response to them. Materials and methods: Descriptive, cross-sectional and retrospective...
| Autores principales: | , , , |
|---|---|
| Formato: | Artículo revista |
| Publicado: |
Universidad Nacional Córdoba. Facultad de Ciencias Médicas. Secretaria de Ciencia y Tecnología
2021
|
| Materias: | |
| Acceso en línea: | https://revistas.unc.edu.ar/index.php/med/article/view/34914 |
| Aporte de: |
| id |
I10-R327-article-34914 |
|---|---|
| record_format |
ojs |
| institution |
Universidad Nacional de Córdoba |
| institution_str |
I-10 |
| repository_str |
R-327 |
| container_title_str |
Revista de la Facultad de Ciencias Médicas de Córdoba |
| format |
Artículo revista |
| topic |
SARS-CoV-2 antibodies vaccines RNA SPUTNIK OXFORD-ASTRAZENECA COVISHIELD SINOPHARM SARS-CoV-2 anticuerpos vacunas ARN SPUTNIK ASTRAZENECA SINOPHARM . |
| spellingShingle |
SARS-CoV-2 antibodies vaccines RNA SPUTNIK OXFORD-ASTRAZENECA COVISHIELD SINOPHARM SARS-CoV-2 anticuerpos vacunas ARN SPUTNIK ASTRAZENECA SINOPHARM . Pedranti , MS Adamo , MP Cruz, R Peano, N Quantitative detection of ANTI-PROTEIN S antibodies of SARS-CoV-2 in vaccinated personnel of Fundación para el Progreso de la Medicina (Foundation for the Progress of Medicine), city of Córdoba, Argentina |
| topic_facet |
SARS-CoV-2 antibodies vaccines RNA SPUTNIK OXFORD-ASTRAZENECA COVISHIELD SINOPHARM SARS-CoV-2 anticuerpos vacunas ARN SPUTNIK ASTRAZENECA SINOPHARM . |
| author |
Pedranti , MS Adamo , MP Cruz, R Peano, N |
| author_facet |
Pedranti , MS Adamo , MP Cruz, R Peano, N |
| author_sort |
Pedranti , MS |
| title |
Quantitative detection of ANTI-PROTEIN S antibodies of SARS-CoV-2 in vaccinated personnel of Fundación para el Progreso de la Medicina (Foundation for the Progress of Medicine), city of Córdoba, Argentina |
| title_short |
Quantitative detection of ANTI-PROTEIN S antibodies of SARS-CoV-2 in vaccinated personnel of Fundación para el Progreso de la Medicina (Foundation for the Progress of Medicine), city of Córdoba, Argentina |
| title_full |
Quantitative detection of ANTI-PROTEIN S antibodies of SARS-CoV-2 in vaccinated personnel of Fundación para el Progreso de la Medicina (Foundation for the Progress of Medicine), city of Córdoba, Argentina |
| title_fullStr |
Quantitative detection of ANTI-PROTEIN S antibodies of SARS-CoV-2 in vaccinated personnel of Fundación para el Progreso de la Medicina (Foundation for the Progress of Medicine), city of Córdoba, Argentina |
| title_full_unstemmed |
Quantitative detection of ANTI-PROTEIN S antibodies of SARS-CoV-2 in vaccinated personnel of Fundación para el Progreso de la Medicina (Foundation for the Progress of Medicine), city of Córdoba, Argentina |
| title_sort |
quantitative detection of anti-protein s antibodies of sars-cov-2 in vaccinated personnel of fundación para el progreso de la medicina (foundation for the progress of medicine), city of córdoba, argentina |
| description |
Abstract
Vaccination against SARS-CoV-2 began in Argentina in December 2020. We measured the concentration of antibodies generated by the different vaccines and doses with the aim of evaluating the humoral immune response to them.
Materials and methods: Descriptive, cross-sectional and retrospective study. IgG anti-protein S antibodies of SARS-CoV-2 (ABBOTT) were quantitatively determined in sera from 41 staff members at Fundación para el Progreso de la Medicina (Foundation for the Progress of Medicine). The study was approved by the Comité de Investigación y Docencia institucional (Institutional Research and Teaching Committee). The inclusion criteria covered vaccinated personnel. Results: the mean age was 40 ± 9 years (25 to 62). 33 participants were female, and 33 participants did not have the infection. 33 received both doses. We evaluated 1 to 9 blood samples per participant from January to June 2021. Average: 3± 2 samples. Total: 134 samples. 23 participants were vaccinated with Sputnik V, 12 with Oxford-AstraZeneka-Covishield and 6 with Sinopharm. Participants with or without infection and with one or both doses were grouped together. With previous infection, the post-first dose value was 20800.27 ± 14004 (4267.5 to 36057.3). The average follow-up time was 31 days after administration. For the second dose, the follow-up time was 61 days; and the average antibody concentration was 11175.65 ± 10248.74 (2019.9 to 32618.5). There were no differences between doses (p: 0.7220). There was a difference when compared with those who did not have the infection (p<0.0001). No significant differences were observed between vaccines, regardless of what dose was administered (1st dose, p: 0.6824; 2nd dose, p: 0.5549). In uninfected: Oxford-AstraZeneca-Covishield 1 average dose 504.8 ± 1097.9, and with 2 doses 2223.48 ± 2906.8 (p<0.0001), Sinopharm 62.2 ± 59.4 and 937.7 ± 467.2 respectively (p<0.0001), Sputnik V, 213.2 ± 352.4 and 1893.3 ± 2347.7 (p<0.0001). All participants generated antibodies after being vaccinated.
Conclusions-Relevance of the work: The three vaccines evaluated generated a statistically similar anti-S antibody immune response with high effectiveness. Those who get the infection before or after getting vaccinated reach statistically higher levels of antibodies. The second doses generate statistically higher levels of antibodies in uninfected participants. |
| publisher |
Universidad Nacional Córdoba. Facultad de Ciencias Médicas. Secretaria de Ciencia y Tecnología |
| publishDate |
2021 |
| url |
https://revistas.unc.edu.ar/index.php/med/article/view/34914 |
| work_keys_str_mv |
AT pedrantims quantitativedetectionofantiproteinsantibodiesofsarscov2invaccinatedpersonneloffundacionparaelprogresodelamedicinafoundationfortheprogressofmedicinecityofcordobaargentina AT adamomp quantitativedetectionofantiproteinsantibodiesofsarscov2invaccinatedpersonneloffundacionparaelprogresodelamedicinafoundationfortheprogressofmedicinecityofcordobaargentina AT cruzr quantitativedetectionofantiproteinsantibodiesofsarscov2invaccinatedpersonneloffundacionparaelprogresodelamedicinafoundationfortheprogressofmedicinecityofcordobaargentina AT peanon quantitativedetectionofantiproteinsantibodiesofsarscov2invaccinatedpersonneloffundacionparaelprogresodelamedicinafoundationfortheprogressofmedicinecityofcordobaargentina AT pedrantims deteccioncuantitativadeanticuerposantiproteinasdelsarscov2enpersonalvacunadodelafundacionparaelprogresodelamedicina AT adamomp deteccioncuantitativadeanticuerposantiproteinasdelsarscov2enpersonalvacunadodelafundacionparaelprogresodelamedicina AT cruzr deteccioncuantitativadeanticuerposantiproteinasdelsarscov2enpersonalvacunadodelafundacionparaelprogresodelamedicina AT peanon deteccioncuantitativadeanticuerposantiproteinasdelsarscov2enpersonalvacunadodelafundacionparaelprogresodelamedicina AT pedrantims a AT adamomp a AT cruzr a AT peanon a |
| first_indexed |
2024-09-03T21:02:46Z |
| last_indexed |
2024-09-03T21:02:46Z |
| _version_ |
1809210268572450816 |
| spelling |
I10-R327-article-349142024-04-15T16:19:09Z Quantitative detection of ANTI-PROTEIN S antibodies of SARS-CoV-2 in vaccinated personnel of Fundación para el Progreso de la Medicina (Foundation for the Progress of Medicine), city of Córdoba, Argentina Detección cuantitativa de anticuerpos Anti Proteína S del SARS-CoV-2 en personal vacunado de la Fundación para el Progreso de la Medicina A Pedranti , MS Adamo , MP Cruz, R Peano, N SARS-CoV-2 antibodies vaccines RNA SPUTNIK OXFORD-ASTRAZENECA COVISHIELD SINOPHARM SARS-CoV-2 anticuerpos vacunas ARN SPUTNIK ASTRAZENECA SINOPHARM . Abstract Vaccination against SARS-CoV-2 began in Argentina in December 2020. We measured the concentration of antibodies generated by the different vaccines and doses with the aim of evaluating the humoral immune response to them. Materials and methods: Descriptive, cross-sectional and retrospective study. IgG anti-protein S antibodies of SARS-CoV-2 (ABBOTT) were quantitatively determined in sera from 41 staff members at Fundación para el Progreso de la Medicina (Foundation for the Progress of Medicine). The study was approved by the Comité de Investigación y Docencia institucional (Institutional Research and Teaching Committee). The inclusion criteria covered vaccinated personnel. Results: the mean age was 40 ± 9 years (25 to 62). 33 participants were female, and 33 participants did not have the infection. 33 received both doses. We evaluated 1 to 9 blood samples per participant from January to June 2021. Average: 3± 2 samples. Total: 134 samples. 23 participants were vaccinated with Sputnik V, 12 with Oxford-AstraZeneka-Covishield and 6 with Sinopharm. Participants with or without infection and with one or both doses were grouped together. With previous infection, the post-first dose value was 20800.27 ± 14004 (4267.5 to 36057.3). The average follow-up time was 31 days after administration. For the second dose, the follow-up time was 61 days; and the average antibody concentration was 11175.65 ± 10248.74 (2019.9 to 32618.5). There were no differences between doses (p: 0.7220). There was a difference when compared with those who did not have the infection (p<0.0001). No significant differences were observed between vaccines, regardless of what dose was administered (1st dose, p: 0.6824; 2nd dose, p: 0.5549). In uninfected: Oxford-AstraZeneca-Covishield 1 average dose 504.8 ± 1097.9, and with 2 doses 2223.48 ± 2906.8 (p<0.0001), Sinopharm 62.2 ± 59.4 and 937.7 ± 467.2 respectively (p<0.0001), Sputnik V, 213.2 ± 352.4 and 1893.3 ± 2347.7 (p<0.0001). All participants generated antibodies after being vaccinated. Conclusions-Relevance of the work: The three vaccines evaluated generated a statistically similar anti-S antibody immune response with high effectiveness. Those who get the infection before or after getting vaccinated reach statistically higher levels of antibodies. The second doses generate statistically higher levels of antibodies in uninfected participants. Resumen: La vacunación contra el SARS-CoV-2 comenzó en Argentina en diciembre de 2020. Medimos concentración de anticuerpos generados por las diferentes vacunas y dosis con el Objetivo de evaluar la respuesta inmune humoral a las mismas. Materiales y métodos: Estudio descriptivo, transversal y retrospectivo. Se determinaron cuantitativamente anticuerpos IgG Anti proteína S del SARS-CoV-2 (ABBOTT) en sueros de 41 trabajadores de la Fundación para el Progreso de la Medicina. El estudio fue aprobado por el comité de Investigación y Docencia institucional. El criterio de inclusión abarcó a personal vacunado. Resultados: la edad promedio fue 40 ± 9 años (25 a 62). 33 fueron femeninos, y 33 no tuvieron la infección. 33 recibieron las dos dosis. Se evaluaron de 1 a 9 muestras de sangre por participante de enero a junio de 2021. Promedio 3± 2 muestras. Total 134 muestras. 23 personas fueron vacunadas con Sputnik V, 12 con Oxford-AstraZeneka-Covishield y 6 con Sinopharm . Se agruparon los participantes con o sin infección y con una dosis o ambas. Con infección previa el valor post primera dosis fue 20800,27 ± 14004 (4267,5 a 36057,3). El tiempo promedio de seguimiento fue de 31 días luego de la colocación. Para la segunda dosis fue de 61 días; y la concentración de anticuerpos promedio fue 11175,65 ± 10248,74 (2019,9 a 32618,5). No hubo diferencias entre dosis (p: 0,7220). Hubo diferencia al comparar con los que no tuvieron infección (p<0,0001). No se observaron diferencias significativas entre vacunas, independientemente de cual era la dosis colocada (1ra dosis, p: 0,6824; 2da dosis, p: 0,5549). En no infectados: Oxford-AstraZeneca-Covishield 1 dosis promedio 504,8 ± 1097,9, y con 2 dosis 2223,48 ± 2906,8 (p<0,0001), Sinopharm 62,2 ± 59,4 y 937,7 ± 467,2 respectivamente (p<0,0001), Sputnik V, 213,2 ± 352,4 y 1893,3 ± 2347,7 (p<0,0001). Todos los participantes generaron anticuerpos luego de ser vacunados. Conclusiones-Relevancia del trabajo: Las tres vacunas evaluadas generaron una respuesta inmune de anticuerpos anti-S estadísticamente similar con alta efectividad. Aquellos que contraen la infección antes o después de vacunarse alcanzan niveles estadísticamente superiores de anticuerpos. Las segundas dosis generan niveles estadísticamente superiores de anticuerpos en no infectados. . Universidad Nacional Córdoba. Facultad de Ciencias Médicas. Secretaria de Ciencia y Tecnología 2021-10-12 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion texto texto texto https://revistas.unc.edu.ar/index.php/med/article/view/34914 Revista de la Facultad de Ciencias Médicas de Córdoba.; Vol. 78 No. Suplemento (2021): Suplemento JIC XXII Revista de la Facultad de Ciencias Médicas de Córdoba; Vol. 78 Núm. Suplemento (2021): Suplemento JIC XXII Revista da Faculdade de Ciências Médicas de Córdoba; v. 78 n. Suplemento (2021): Suplemento JIC XXII 1853-0605 0014-6722 http://creativecommons.org/licenses/by-nc/4.0 |